[ Inside the business ]

NVS stock analysis

NVS · Novartis Ag

Pharmaceutical preparations.

Nothing unusual in its latest filings.

The future, in 7 questions

01 What's priced in?Not available

Needs today's sales, share count and price.

02 Is the wave rising?No Radar technology matched

Not among the companies mentioning Radar's technologies most.

03 Will customers keep buying?No customer data
No customer over 10%
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Not enough data
06 Can it fund itself?Not available
07 What could break it?1 to watch
  • Moves strongly with the S&P 500

From SEC filings, price and Radar. Not advice.

The record

Early signals

Quiet.

What could go wrong

Steadier than most.

It has moved 0.5× the market. In the 2008 crisis it fell 27% while the market fell 51%.

What they sell

Not broken out.

The filings don't split revenue by product in structured data.

Where each dollar goes

Not available.

Cost lines aren't reported in a comparable form.

Its market

1.5× the economy.

The government expects its industry, pharmaceutical and medicine manufacturing, to grow 3.0% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Not applicable.

Cash flow patterns don't describe a life cycle for banks and insurers, or the totals aren't reported.

Earnings quality

Can't score.

The inputs aren't in its structured filings.

Competitive advantage

Not measurable.

Returns on capital can't be computed from its filings (common for banks and insurers).

Future bets

Not reported.

No research, equipment or commitment figures in its structured filings.

All figures from Novartis Ag's SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.